Indoco Remedies Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/o1uzujajyvw2n6l95m52a2dc.pdf

Key Takeaways


Europe: The Quarter's Biggest Drag

Aditi Panandikar: "this quarter's performance does not yet have any impact of the Red Sea issues. I think the Europe picture that you are seeing is largely an impact of Paracetamol from one customer orders steady state not coming in possibly because they are overstocked."

Domestic Business: Tail Wind-Down Masks Underlying Health

Aditi Panandikar: "if you look at our performance for Q3 as per AVAX then against a covered market growth of 8% we are actually growing at 12.8% this quarter. That shows very healthy demand for our products."

US Business: Ramping Toward ₹300 Crore

Sundeep Bambolkar: "As we said futuristic statements not everything is under our control. Geopolitics is playing a huge spoil sport but still we are trying our best. Last year we had done Rs.266 Crores and this year we will end up very close to the figure you mentioned."

Margins: Multiple Headwinds, Some Transitory


API & Other Businesses: Diversification Paying Off


Capacity & Long-Term Ambition

Aditi Panandikar: "Actually this capacity can give us anywhere from 2.5 to 3 times the top line."

Guidance & Commitments

CommitmentSpecificsTimeline
US business revenueEnd the year very close to ₹300 croreFY2024 exit
Remediation costsSimilar level of costs to continue, then drop offOne more quarter
Europe turnaroundOrders resume; new product approvals drive visible improvementFrom February (orders), April/May (approvals)
Domestic product tail wind-downWeeding of 150+ small products to completeBy end of FY2024
Tax rateRemain at concessional rate of 25%Ongoing
CapexSimilar to FY2024 (₹150 crore) or slightly lowerFY2025
Goa Plant 2 FDA re-inspectionExpected in second half of next yearQ3 FY2025 earliest
US ANDA approvalsTwo to three approvals possibleWithin a year

Key Metrics

MetricQ3 FY24
Net revenue₹448.4 cr, +9.2% YoY vs ₹410.6 cr
EBITDA margin14.6%, vs 15% in Q3 FY23
PAT before exceptional items margin6.3% at ₹28.2 cr, vs 6.8% at ₹27.9 cr in Q3 FY23
EPS₹2.17, vs ₹3.02 in Q3 FY23
Domestic formulation revenue₹212.6 cr, +4.4% YoY vs ₹203.6 cr
International formulation revenue₹194.7 cr, +4.6% YoY vs ₹186.1 cr
US business revenue₹86.3 cr, +43.2% YoY vs ₹60.3 cr
Europe revenue₹58.2 cr, degrowth vs ₹86 cr in Q3 FY23
Emerging markets revenue₹47.2 cr, +37.3% YoY vs ₹34.4 cr
API business revenue₹33.3 cr, +105% YoY vs ₹16.2 cr
AnaCipher CRO and Indoco Analytical Solutions revenue₹7.8 cr, +70% YoY vs ₹4.6 cr
Material cost as % of sales30.5%, vs 31.7% in Q3 FY23
One-off costs (remediation plus VRS)~₹13–15 cr (management estimate)
Domestic covered market growth (AWACS)12.8% for Indoco vs 8% market growth
Domestic MR count on payroll2,300
Capex expected for FY24₹150 cr